<DOC>
	<DOCNO>NCT02105467</DOCNO>
	<brief_summary>This efficacy safety study grazoprevir ( MK-5172 ) combination elbasvir ( MK-8742 ) treatment-naive participant chronic hepatitis C virus ( HCV ) genotype ( GT ) 1 , 4 , 6 infection . Participants randomly assign ( 3:1 ratio ) immediate treatment defer treatment ( placebo control ) . The primary efficacy hypothesis proportion participant receive combination therapy Immediate Treatment Arm achieve sustain viral response 12 week end study treatment ( SVR12 ) superior 73 % .</brief_summary>
	<brief_title>Study Efficacy Safety Grazoprevir ( MK-5172 ) /Elbasvir ( MK-8742 ) Combination Regimen Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1 , 4 , 6 ( MK-5172-060 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Inclusion criterion : Documented chronic HCV GT1 , GT4 , GT6 evidence nontypeable mixed genotype infection ( positive antiHCV antibody , HCV RNA , list GTs least 6 month prior screen must confirm screen lab result ) Cirrhosis define : liver biopsy show cirrhosis METAVIR F4 ; Fibroscan show cirrhosis result &gt; 12.5 kiloPascals ( kPa ) ; FibroSure® ( Fibrotest® ) score &gt; 0.75 aspartate aminotransferase ( AST ) : platelet ratio index ( APRI ) &gt; 2 Absence cirrhosis define : liver biopsy show absence cirrhosis , Fibroscan result ≤12.5 kPa , Fibrosure® ( Fibrotest® ) score &lt; = 0.48 APRI &lt; =1 HCV treatment status treatment naïve ( naïve antiHCV treatment ) also ineligible take pegylated interferon Female participant reproductive potential , female reproductive potential agree avoid become pregnant receiving study drug 14 day last dose study drug ( use abstinence acceptable method contraception ) Exclusion criterion : Evidence decompensated liver disease manifest presence history ascites , esophageal gastric variceal bleeding , hepatic encephalopathy sign symptom advance liver disease . For cirrhotics , participant ChildPugh Class B C PughTurcotte ( CPT ) score &gt; 6 Coinfection hepatitis B virus human immunodeficiency virus ( HIV ) History malignancy &lt; =5 year prior sign inform consent except adequately treat basal cell squamous cell skin cancer situ cervical cancer carcinoma situ ; evaluation active suspected malignancy Evidence hepatocellular carcinoma ( HCC ) evaluation HCC Currently participate participate study investigational compound within 30 day sign informed consent willing refrain participate another study course study Clinicallyrelevant drug alcohol abuse within 12 month screen Pregnant , breastfeeding , expect conceive donate egg Day 1 throughout treatment 14 day last dose study medication longer dictate local regulation Organ transplant ( include hematopoietic stem cell transplant ) cornea hair Poor venous access History gastric surgery ( e.g. , staple , bypass ) history malabsorption disorder ( e.g. , celiac sprue disease ) Any medical condition requiring , likely require , chronic systemic administration corticosteroid , TNF antagonists , immunosuppressant drug course trial Evidence history chronic hepatitis cause HCV , include limited nonalcoholic steatohepatitis ( NASH ) , druginduced hepatitis , autoimmune hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>